European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.

L Gossec, J S Smolen, C Gaujoux-Viala, Z Ash, H Marzo-Ortega, D van der Heijde, O Fitzgerald, D Aletaha, P Balint, D Boumpas, J Braun, F C Breedveld, G Burmester, J D Cañete, M de Wit, H Dagfinrud, K de Vlam, M Dougados, P Helliwell, A Kavanaugh & 15 others T K Kvien, R Landewé, T Luger, M Maccarone, D McGonagle, Neil J McHugh, I B McInnes, C Ritchlin, J Sieper, P P Tak, G Valesini, J Vencovsky, K L Winthrop, A Zink, P Emery

Research output: Contribution to journalArticle

  • 303 Citations

Abstract

BACKGROUND: Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD).
METHODS: The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement.
RESULTS: Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined.
CONCLUSION: These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.
LanguageEnglish
Pages4-12
Number of pages9
JournalAnnals of the Rheumatic Diseases
Volume71
Issue number1
Early online date26 Sep 2011
DOIs
StatusPublished - Jan 2012

Fingerprint

Psoriatic Arthritis
Antirheumatic Agents
Pharmacology
Anti-Inflammatory Agents
Biological Factors
Therapeutics
Joints
Pharmaceutical Preparations
Glucocorticoids
Expert Testimony
Advisory Committees
Rheumatic Diseases
Research

Cite this

Gossec, L., Smolen, J. S., Gaujoux-Viala, C., Ash, Z., Marzo-Ortega, H., van der Heijde, D., ... Emery, P. (2012). European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. DOI: 10.1136/annrheumdis-2011-200350

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. / Gossec, L; Smolen, J S; Gaujoux-Viala, C; Ash, Z; Marzo-Ortega, H; van der Heijde, D; Fitzgerald, O; Aletaha, D; Balint, P; Boumpas, D; Braun, J; Breedveld, F C; Burmester, G; Cañete, J D; de Wit, M; Dagfinrud, H; de Vlam, K; Dougados, M; Helliwell, P; Kavanaugh, A; Kvien, T K; Landewé, R; Luger, T; Maccarone, M; McGonagle, D; McHugh, Neil J; McInnes, I B; Ritchlin, C; Sieper, J; Tak, P P; Valesini, G; Vencovsky, J; Winthrop, K L; Zink, A; Emery, P.

In: Annals of the Rheumatic Diseases, Vol. 71, No. 1, 01.2012, p. 4-12.

Research output: Contribution to journalArticle

Gossec, L, Smolen, JS, Gaujoux-Viala, C, Ash, Z, Marzo-Ortega, H, van der Heijde, D, Fitzgerald, O, Aletaha, D, Balint, P, Boumpas, D, Braun, J, Breedveld, FC, Burmester, G, Cañete, JD, de Wit, M, Dagfinrud, H, de Vlam, K, Dougados, M, Helliwell, P, Kavanaugh, A, Kvien, TK, Landewé, R, Luger, T, Maccarone, M, McGonagle, D, McHugh, NJ, McInnes, IB, Ritchlin, C, Sieper, J, Tak, PP, Valesini, G, Vencovsky, J, Winthrop, KL, Zink, A & Emery, P 2012, 'European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.' Annals of the Rheumatic Diseases, vol. 71, no. 1, pp. 4-12. DOI: 10.1136/annrheumdis-2011-200350
Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases. 2012 Jan;71(1):4-12. Available from, DOI: 10.1136/annrheumdis-2011-200350
Gossec, L ; Smolen, J S ; Gaujoux-Viala, C ; Ash, Z ; Marzo-Ortega, H ; van der Heijde, D ; Fitzgerald, O ; Aletaha, D ; Balint, P ; Boumpas, D ; Braun, J ; Breedveld, F C ; Burmester, G ; Cañete, J D ; de Wit, M ; Dagfinrud, H ; de Vlam, K ; Dougados, M ; Helliwell, P ; Kavanaugh, A ; Kvien, T K ; Landewé, R ; Luger, T ; Maccarone, M ; McGonagle, D ; McHugh, Neil J ; McInnes, I B ; Ritchlin, C ; Sieper, J ; Tak, P P ; Valesini, G ; Vencovsky, J ; Winthrop, K L ; Zink, A ; Emery, P. / European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.In: Annals of the Rheumatic Diseases. 2012 ; Vol. 71, No. 1. pp. 4-12
@article{3b9421f2fc424a87a9da2800f351466f,
title = "European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.",
abstract = "BACKGROUND: Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). METHODS: The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. RESULTS: Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. CONCLUSION: These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.",
author = "L Gossec and Smolen, {J S} and C Gaujoux-Viala and Z Ash and H Marzo-Ortega and {van der Heijde}, D and O Fitzgerald and D Aletaha and P Balint and D Boumpas and J Braun and Breedveld, {F C} and G Burmester and Ca{\~n}ete, {J D} and {de Wit}, M and H Dagfinrud and {de Vlam}, K and M Dougados and P Helliwell and A Kavanaugh and Kvien, {T K} and R Landew{\'e} and T Luger and M Maccarone and D McGonagle and McHugh, {Neil J} and McInnes, {I B} and C Ritchlin and J Sieper and Tak, {P P} and G Valesini and J Vencovsky and Winthrop, {K L} and A Zink and P Emery",
year = "2012",
month = "1",
doi = "10.1136/annrheumdis-2011-200350",
language = "English",
volume = "71",
pages = "4--12",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.

AU - Gossec,L

AU - Smolen,J S

AU - Gaujoux-Viala,C

AU - Ash,Z

AU - Marzo-Ortega,H

AU - van der Heijde,D

AU - Fitzgerald,O

AU - Aletaha,D

AU - Balint,P

AU - Boumpas,D

AU - Braun,J

AU - Breedveld,F C

AU - Burmester,G

AU - Cañete,J D

AU - de Wit,M

AU - Dagfinrud,H

AU - de Vlam,K

AU - Dougados,M

AU - Helliwell,P

AU - Kavanaugh,A

AU - Kvien,T K

AU - Landewé,R

AU - Luger,T

AU - Maccarone,M

AU - McGonagle,D

AU - McHugh,Neil J

AU - McInnes,I B

AU - Ritchlin,C

AU - Sieper,J

AU - Tak,P P

AU - Valesini,G

AU - Vencovsky,J

AU - Winthrop,K L

AU - Zink,A

AU - Emery,P

PY - 2012/1

Y1 - 2012/1

N2 - BACKGROUND: Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). METHODS: The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. RESULTS: Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. CONCLUSION: These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.

AB - BACKGROUND: Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). METHODS: The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. RESULTS: Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. CONCLUSION: These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.

UR - http://www.scopus.com/inward/record.url?scp=82955236087&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1136/annrheumdis-2011-200350

U2 - 10.1136/annrheumdis-2011-200350

DO - 10.1136/annrheumdis-2011-200350

M3 - Article

VL - 71

SP - 4

EP - 12

JO - Annals of the Rheumatic Diseases

T2 - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 1

ER -